Van Dyke, MD, Dawn Sokol, MD, Cheryl A
Van Dyke, MD, Dawn Sokol, MD, Cheryl A. associated with a decrease in viral failure after 12 weeks on a ZDV-containing HAART regimen (P = 0.017). Conclusion No increase was seen in the rate of viral failure after HAART associated with the presence of resistance mutations at baseline. This paradoxical result may be due to…